Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Fludarabine
Synonyms
Therapy Description

Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Fludarabine Fludara FAMP|Fludarabine phosphate Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting
NCT02118285 Phase I Aldesleukin Epacadostat Cyclophosphamide Fludarabine Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Completed
NCT02412475 Phase I Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine Epigenetic Reprogramming in Relapse AML Terminated
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Recruiting
NCT02250937 Phase II Cladribine Busulfan Busulfan + Venetoclax Fludarabine Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting
NCT03602157 Phase I Bendamustine Fludarabine ATLCAR.CD30.CCR4 cells ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL Recruiting
NCT00074490 Phase II Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Terminated
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Active, not recruiting
NCT03263936 Phase I Vorinostat Decitabine Cytarabine Fludarabine Filgrastim Epigenetic Reprogramming in Relapse/Refractory AML Recruiting
NCT02118311 Phase II Fludarabine Cyclophosphamide T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation Withdrawn
NCT01312376 Phase I Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer Terminated
NCT03860844 Phase II Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Recruiting
NCT03190941 Phase I Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients Recruiting
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting
NCT02756572 Phase I Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed
NCT02551718 Phase I Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting
NCT01231412 Phase III Sirolimus Fludarabine Cyclosporine + Mycophenolate mofetil Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed
NCT02472392 Phase I Fludarabine Cyclophosphamide Melphalan Busulfan anti-thymocyte globulin Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma Completed
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Active, not recruiting
NCT00305682 Phase II Sirolimus Mycophenolate mofetil anti-thymocyte globulin Cyclophosphamide Fludarabine Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Active, not recruiting
NCT01529827 Phase II Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01707004 Phase I Cyclophosphamide Decitabine Filgrastim Fludarabine Busulfan Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
NCT01659151 Phase II Aldesleukin Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma Active, not recruiting
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Active, not recruiting
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting
NCT02181478 Phase I Fludarabine Cyclophosphamide Intra-Osseous Co-Transplant of UCB and hMSC Active, not recruiting
NCT01822652 Phase I Cyclophosphamide Fludarabine Pembrolizumab 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Active, not recruiting
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Recruiting


Additional content available in CKB BOOST